<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tolvaptan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06212</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (<span class="caps">SIADH</span>). <span class="caps">FDA</span> approved on May 19, 2009.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06212/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06212/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06212.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06212.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06212.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06212.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06212.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06212">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Samsca </td><td>Otsuka Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasopressin-receptor-antagonists">Vasopressin receptor antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>150683-30-0</td></tr><tr><th>Weight</th><td>Average: 448.941<br>Monoisotopic: 448.155370383</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>GYHCTFXIZSNGJT-XMMPIXPASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)/t24-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzamides</td></tr><tr><th>Direct parent</th><td>N-phenylbenzamides</td></tr><tr><th>Alternative parents</th><td>Benzazepines; Anilides; Benzoyl Derivatives; Toluenes; Chlorobenzenes; Azepines; Aryl Chlorides; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Secondary Alcohols; Tertiary Amines; Carboxylic Acids; Enolates; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>benzazepine; acetanilide; benzoyl; toluene; azepine; chlorobenzene; aryl chloride; aryl halide; tertiary carboxylic acid amide; secondary alcohol; carboxamide group; tertiary amine; secondary carboxylic acid amide; polyamine; carboxylic acid; carboxylic acid derivative; enolate; organohalogen; amine; organochloride; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the n-phenylbenzamides.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis. </td></tr><tr><th>Pharmacodynamics</th><td>Urine volume and fluid intake increase in a dose dependent manner which results in overall negative fluid balance in patients taking tolvaptan. Increases in serum sodium and osmolality can be observed 4-8 hours post-administration and is maintained for 24 hours. The magnitude of serum sodium and osmolality change increases with escalating doses. Furthermore, a decrease in urine osmolality and increase in free water clearance can be observed 4 hours after post-administration of tolvaptan. The affinity for V2 receptors is 29x greater than that of V1a receptors and does not have any appreciable affinity for V2 receptors. </td></tr><tr><th>Mechanism of action</th><td>Tolvaptan is a selective and competitive arginine vasopressin receptor 2 antagonist. Vasopressin acts on the V2 receptors found in the walls of the vasculature and luminal membranes of renal collecting ducts. By blocking V2 receptors in the renal collecting ducts, aquaporins do not insert themselves into the walls thus preventing water absorption. This action ultimately results in an increase in urine volume, decrease urine osmolality, and increase electrolyte-free water clearance to reduce intravascular volume and an increase serum sodium levels. Tolvaptan is especially useful for heart failure patients as they have higher serum levels of vasopressin. </td></tr><tr><th>Absorption</th><td>Tmax, Healthy subjects: 2 - 4 hours;
Cmax, Healthy subjects, 30 mg: 374 ng/mL;
Cmax, Healthy subjects, 90 mg: 418 ng/mL;
Cmax, heart failure patients, 30 mg: 460 ng/mL;
Cmax, heart failure patients, 90 mg: 723 ng/mL;
AUC(0-24 hours), 60 mg: 3.71 &#956;g&#183;h/mL;
AUC(&#8734;), 60 mg: 4.55 &#956;g&#183;h/mL;
The pharmacokinetic properties of tolvaptan are stereospecific, with a steady-state ratio of the S-(-) to the R-(+) enantiomer of about 3. The absolute bioavailability of tolvaptan is unknown. At least 40% of the dose is absorbed as tolvaptan or metabolites. Food does not impact the bioavailability of tolvaptan. </td></tr><tr><th>Volume of distribution</th><td><p>Healthy subjects: 3L/kg; slightly higher in heart failure patients.</p></td></tr><tr><th>Protein binding</th><td>99% bound </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism exclusively by CYP3A4 enzyme in the liver. Metabolites are inactive.  </p></td></tr><tr><th>Route of elimination</th><td>Fecal- very little renal elimination (</td></tr><tr><th>Half life</th><td>Terminal half life, oral dose = 12 hours. </td></tr><tr><th>Clearance</th><td><p>4 mL/min/kg (post-oral dosing).</p></td></tr><tr><th>Toxicity</th><td>The oral LD50 of tolvaptan in rats and dogs is &gt;2000 mg/kg. Most common adverse reactions (&#8805;5% placebo) are thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, and hyperglycemia. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.961</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8429</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5116</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6765</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5241</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5525</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.767</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7217</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7662</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7372</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7512</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7214</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7887</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5308</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8545</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5874</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7247
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8623
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9939
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2269 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9807
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.682
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Otsuka america pharmaceutical inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>15 mg, 30 mg, 60 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01483">Barbital</a></td><td>Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB01128">Bicalutamide</a></td><td>CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. </td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. </td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Tolvaptan may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan by decreasing its metabolism. Concomitant therapy is contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>